Diagnostics & imaging AI · AI breast cancer risk prediction
Clairity
Clairity is a Boston company whose Clairity Breast software is the first FDA-authorized AI that predicts a woman's five-year risk of breast cancer from a routine screening mammogram, giving clinicians and patients a basis for personalized screening.
Strong fit
- Breast imaging programs that want risk results from mammograms they already take
- Health systems building risk-based screening for women who may need MRI or closer follow-up
- Women who want their own risk estimate through Everlywell
Weak fit
- Programs without counseling or follow-up capacity for women flagged as higher risk
- Buyers looking for AI that finds cancer on today's mammogram
- Sites that only use 3D tomosynthesis images, since the current model reads 2D mammograms
Bottom line
Clairity Breast reads a routine screening mammogram and estimates a woman's chance of developing breast cancer over the next five years, using patterns in breast tissue the eye cannot see. It suits imaging programs and health systems that want to move toward risk-based screening. Since October 2026 women can also order it through Everlywell.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Clairity's customers are breast imaging centers, health systems, and, through Everlywell, women themselves. Clairity Breast analyzes a 2D screening mammogram at the pixel level and returns a five-year risk estimate. Clinicians use it to find women who may need earlier, more frequent, or supplemental screening such as MRI. The model was trained on millions of images and validated on more than 77,000 mammograms from five screening centers, according to the company's about page.
Most programs today estimate risk with questionnaire-based models built on age, family history, and breast density. Clairity Breast adds an image-based estimate. Cancer detection AI such as ScreenPoint Medical and Therapixel answers a different question, whether a cancer is visible now, so many sites would use both. Consumer pricing is $249 through Everlywell, and provider pricing is by contract.
The science behind Clairity comes from founder Connie Lehman's work with MIT professor Regina Barzilay, whose 2019 deep learning model placed 31% of future cancer patients in its highest risk group, compared with 18% for traditional models. Clairity was founded in 2020 and won FDA De Novo authorization in June 2025. In November 2025 it raised $43 million in a Series B led by ACE Global Equity and Santé Ventures. Its revenue is an estimated $3 million a year.
The main limit is what happens after a high score. A risk number helps only if the program has counseling, MRI access, and follow-up ready, and the current product reads 2D mammograms only.
What clinicians and buyers say
What people like
"Getting a five-year risk number from the mammogram we already have fills a gap that family history questionnaires leave."
"Validation across several screening centers matters when we counsel women who are poorly represented in older risk models."
What people don't like
"A high risk score only helps if we have counseling and MRI slots ready."
"Provider pricing is not published, which slows early budget talks."
Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums, and product documentation.
Based on: Clairity homepage, Clairity about page, and pharmaphorum coverage of the Everlywell launch.
Pricing
| Item | Detail |
|---|---|
| Consumer price | $249 through Everlywell for women with a qualifying screening mammogram from the past 12 months, with provider review. |
| Provider model | Contract pricing for imaging centers and health systems. Provider rates are not published. |
| What drives cost | Mammogram volume, reporting integration, and any patient counseling services. |
Leadership
Recent news
- October 2026: Everlywell began offering Clairity Breast nationwide, giving women with a recent screening mammogram access to the five-year risk estimate with provider review.
- November 2025: Clairity raised $43 million in a Series B to expand U.S. commercialization and imaging center partnerships.
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.